Overview

This is a prospective clinical study aiming to test the safety and efficacy of lenvatinib in combination with Aurora kinase A inhibitor VIC-1911 in participate with lenvatinib-unresponsive or lenvatinib-resistant hepatocellular carcinoma(HCC).

Eligibility

Inclusion Criteria:

        (1) Unlimited gender, aged 18-75 years; (2) Meets American Association for the Study of
        Liver Diseases (AASLD) or European Association for the Study of the Liver (EASL) clinical
        diagnostic criteria of hepatocellular carcinoma; (3) Barcelona Clinic Liver Cancer (BCLC)
        Stage C, and there is at least one measurable tumor in the liver (long diameter ≥ 1cm);(4)
        Lenvatinib unresponsive or lenvatinib resistant after standard treatment; (5) Child-Pugh A
        or scored 7 B; (6) Eastern Cooperative Oncology Group performance status score <= 1; (7)
        Platelet count >= 60x10^9/L, Prothrombin time prolonged <= 6 seconds.
        Exclusion Criteria:
        (1) Uncorrectable coagulopathy with obvious bleeding tendency; (2) Patients need long-term
        anticoagulant or anti platelet therapy and cannot stop the drugs; (3) Patients with
        unstable or active ulcer or gastrointestinal bleeding; (4) Heart disease requiring
        treatment or not well controlled high blood pressure; (5) Hepatic encephalopathy or
        refractory ascites requiring treatment; (6) There is a clear active infection; (7)
        Receiving radiotherapy/chemotherapy/interventional therapy for tumor within 4 weeks before
        the start of the study; (8) Severe insufficiency of important organs, such as severe
        cardiopulmonary insufficiency; (9) Other accompanying anti-tumor treatments; (10) The
        investigator assessed that the patient was unable or unwilling to comply with the protocol.